Ascentage Pharma Group International (HKG:6855) raised $126.4 million from its US initial public offering of 7,325,000 American depository shares at $17.25 apiece, a Tuesday press release said.
The drugmaker also granted underwriters a 30-day option to buy up to 1,098,750 more ADSs at the IPO price, with underwriting costs deducted.
J.P. Morgan Securities and Citigroup Global Markets served as the joint book-running managers for the offering.